128 filings
Page 5 of 7
10-K
iuh13shb4vzrr
31 Mar 22
Annual report
8:18am
8-K
5r9gm0xp
30 Mar 22
Results of Operations and Financial Condition
7:40am
8-K
cfooix
21 Mar 22
Departure of Directors or Certain Officers
6:32am
8-K/A
o8wtx4k4
21 Mar 22
Departure of Directors or Certain Officers
6:30am
8-K
rmopn9d9
1 Mar 22
Departure of Directors or Certain Officers
5:07pm
8-K
3t2zesn6rngiqb7huuq
23 Feb 22
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
5:07pm
8-K
6732csc9 qkkcd5i
22 Feb 22
Adagio Therapeutics Announces CEO Succession Plan
7:57am
8-K
1hoawi8k
18 Feb 22
Departure of Directors or Certain Officers
5:29pm
8-K
36pzk 4o91
13 Jan 22
Regulation FD Disclosure
8:01am
8-K
qg5ef5wujg
14 Dec 21
Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant
9:10am
8-K
4to8 ktuyyzswjs6
29 Nov 21
Regulation FD Disclosure
8:23am
8-K
8zx8utfbgjrcj4guo6e
22 Nov 21
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors
5:04pm
8-K
wmpmzbqq1n
16 Nov 21
Regulation FD Disclosure
5:24pm
8-K
31isvpicn7zz15j
15 Nov 21
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
8:08am
8-K
u7qns2w txe
19 Oct 21
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants
4:03pm
8-K
ytkz7qk7 jd
29 Sep 21
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
4:41pm
10-Q
za7r2yq
20 Sep 21
Quarterly report
4:17pm
8-K
tu1gu2v5pdnfrnf8d3
20 Sep 21
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business
4:05pm
8-K
naq8n rr1p
10 Sep 21
Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
7:55am